Abstract
Acquired resistance to BRAF inhibitors such as vemurafenib remains a major challenge in the treatment of BRAF-mutant melanoma. Although mitochondrial dysfunction-mediated pyroptosis has emerged as a potential strategy for overcoming drug resistance, whether MoSe2 possesses intrinsic antitumor activity in the absence of external stimulation remains largely unexplored. Here, we demonstrate that MoSe2 reduces viability and induces lytic cell death to a greater extent in vemurafenib-resistant melanoma cells than in parental cells under the treatment conditions tested. Mechanistically, molecular dynamics simulations and experimental analyses reveal that MoSe2 colocalizes with mitochondria and induces mitochondrial stress, which is associated with mitochondrial dysfunction and activation of the caspase-3/GSDME-associated pyroptotic pathway in vitro. In vivo, adding MoSe2 to vemurafenib is associated with increased intratumoral dendritic cell and Tcell infiltration and with enhanced antitumor efficacy, prolonging survival in both subcutaneous and genetically engineered spontaneous melanoma models, with overall tolerability at the tested dose, although urea and hematological changes were observed. Collectively, this work identifies a previously underappreciated light-independent therapeutic activity of MoSe2 and shows that MoSe2-induced mitochondrial dysfunction is accompanied by caspase-3/GSDME-dependent lytic cell death, while adding MoSe2 to vemurafenib is associated with increased intratumoral immune infiltration and enhanced antitumor efficacy in the models tested.
Keywords:
mitochondria; ROS; MoSe2; melanoma; vemurafenib-resistant; pyroptosis; immune-cell infiltration